Abstract P5-14-23: Preventing alopecia caused by chemotherapy among patients with breast cancer efficacy of applying the cooling hood
Authors: Klimenko Veronika , Semiglazova Tatiana , Kasparov Boris , Krutov Anton , Zernova Margarita , Kondrateva Kristina , Kluge Valeria , Kharchenko Evgenia , Poltoratsky Artem , Khidishyan Karina , Semiglazov Vladislav , Donskih Roman , Krivorotko Petr , Semiglazov Vladimir , Belyaev Aleksey 
Published: March 2020

Background: Alopecia is one of the most frequent adverse event of chemotherapy (CHT) in patients with breast cancer (BC). Alopecia causes many unpleasant feelings, as well as emotional disorders, including depression, especially in women

Aim: to improve the quality of life among BC patients undergoing CHT.

Materials and methods: alopecia prevention procedures were performed by the Cold Caps and Scalp Cooling Systems during various regimens of CHT for 180 BC patients. The mean age of the BC patients was 43 y.o. (from 21 to 73).

The alopecia prevention procedure was performed during CHT and included 3 steps:

1. The preventive cooling cycle took 20-30 minutes to achieve required temperature before proceeding medications.

2. The cooling cycle last during whole CHT.

3. The cooling cycle were continued after CHT and took from 60 to 120 minutes. The duration of post-CHT cycle was dependent on the type of drug and the period of excretion.

Patients received various regimens of CHT, including: antracyclins (47%), taxanes (32%), Cisplatin (5%), Gemcitabine (3,5%), AT (3,5%), CP (9%).

Local hypothermia during various regimens of CHT (n= 988).

Regimens of CHTPatients, n=180Cycles, n= 988n cycles per patientАT (doxorubicin + paclitaxel)6355 (2-6)АС (doxorubicin + cyclophosphamide)864474 (2-6)СР (Carboplatin+ Paclitaxel)15201 (1-4)Paclitaxel584407 (4-12)Cisplatin9302 (2-4)Gemcitabine6162 (2-4)

Alopecia degree evaluated based on СТСАЕ 4.0:

I degree - hair loss of &lt;50% of normal for that individual that is not obvious from a distance but only on close inspection; a different hair style may be required to cover the hair loss but it does not require a wig or hair piece to camouflage.

II degree - hair loss of &gt;=50% normal for that individual that is readily apparent to others; a wig or hair piece is necessary if the patient desires to completely camouflage the hair loss; associated with psychosocial impact.

Results: Among BC patients who were given antracyclins (n=86), 62 (72%) had I degree alopecia, 24 (28%) - II degree alopecia. Among patients who were given taxanes (n=58), 56 (96%) suffered from I degree alopecia, in 2 (4%) of them developed II degree alopecia. Patients who received treatment with Cisplatin (n=9), 7 (78%) of them had I degree alopecia and 2 - II degree alopecia (22%); patients with gemcitabine-based CHT (n=6), suffered from I degree alopecia in 100%.

Patients with AT (n=6), had I degree alopecia in 3 (50%) patients, 3 (50%) suffered from II degree alopecia. In regimens like CP (n=15), 8 (53%) had I degree alopecia, 7 (47%) - II degree alopecia.

Side effects after procedure: 5 (2,8%) patients had headaches, procedure was discontinued for 3 (1,7%) patients because of intolerance to low temperatures.

Conclusions: hypothermia of the hairy part of the head is an effective method of preventing alopecia among BC patients during chemotherapy with antracyclins (72% of cases), taxanes (96%), Cisplatin (78%) and with gemcitabine (100%).

Citation Format: Veronika Klimenko, Tatiana Semiglazova, Boris Kasparov, Anton Krutov, Margarita Zernova, Kristina Kondrateva, Valeria Kluge, Evgenia Kharchenko, Artem Poltoratsky, Karina Khidishyan, Vladislav Semiglazov, Roman Donskih, Petr Krivorotko, Vladimir Semiglazov, Aleksey Belyaev. Preventing alopecia caused by chemotherapy among patients with breast cancer efficacy of applying the cooling hood [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-14-23.